Home   |   News    |   Discussions   |   Books   |   Curiosities
Search
Custom Search
Popular Reads

Earthquakes and animal behavior
LHC may produce time travelling particles
Country boys boast bigger junk
Running the numbers on alien life
Uh-oh, placebo
Forgetful? Blame your house
Pill to blame for rise in prostate cancer?
Cat parasite has global ambitions
Carbon monoxide keeps city dwellers happy
Magnetic field alters moral judgments
Stars manufacturing organic matter?
Unnatural selection: Courtesy of The Pill
Men 2% funnier than women
Parasite rewires sexual attraction
Novel psychiatric drugs take aim at gut bacteria
Discussions
General Science

Not-Quite Science

Physics

Climate Change

Science Fiction

Past Forums

Sponsored Links
Browse

Animal Kingdom

Biology

Climate Change

Environment

Evolution

Genetics

Humans

Mind & Brain

Prehistory

Health & Diet

Health Threats

Health & Environment

Health: From The Lab

Mental Health

Reproductive Health

Energy Alternatives

Chemistry

Computing & Electronics

Nanotechnology

Pimping Nature

Robotics & AI

Physics

Space


Curiosities
Sci Shop
Peculiar and bizarre scientific stuff that you didn't even know existed and you don't need.
Books
Book Reviews
Rusty Rockets lists his all-time favorite science titles.
Archives
2012 2011 2010
2009 2008 2007
2006 2005 2004
2003 2002 2001
2000 1999 1998
Feature Archive


3 November 1998
Scientists Find New Clue To Melanoma Development

For 20 years, Wistar scientist, Meenhard Herlyn, D.V.M., and his research team have been studying the evolution of melanoma, a potentially deadly skin cancer that is expected to strike 40 300 and kill 17 400 Americans this year.

Dr. Herlyn's most recent studies focus on the "switch" that turns benign lesions into malignancies. "This change," says Dr. Herlyn, "determines the outcome of disease. By identifying the genes that turn the switch on, we can design new therapies to keep it turned off."

Thus far, two genes, the Alphav and Beta3, which are found in the vitronectin receptor (a cell surface glycoprotein that promotes the spread of cells and often is found at sites of skin repair), appear to be involved in melanoma development. "Of the two," says Dr. Herlyn, "we believe the Beta3 subunit is most critical." Supporting documentation for this hypothesis appears in yesterday's American Journal of Pathology.

During their early stage of development, melanoma cells remain in the epidermis, which is the upper layer of the skin, and do not infiltrate the dermis, or lower layer. As soon as these cells begin to express the Beta3 subunit of the vitronectin receptor, however, they become highly aggressive, continuously proliferating and deeply invading, which results in high levels of vascular infiltration and an increased rate of metastasis.

As a result of these findings, Dr. Herlyn's group is developing new inhibitors to block the activity of the vitronectin receptor, one of the most interesting and promising targets for the prevention of angiogenesis.

There are five types of lesions that indicate the level of severity in human melanoma: common acquired nevus, dysplastic nevus, radial growth phase (RGP) primary melanoma, vertical growth phase (VGP) primary melanoma, and metastatic melanoma.

The switch from a benign lesion to a malignancy occurs during the RGP primary melanoma stage, though even then, malignant cells grow only within or in close proximity to the epidermis. It is not until the VGP primary melanoma stage that these same cells gain the ability to invade deeply into the dermis. Consequently, it appears that the most critical step in the progression of melanoma occurs between the RGP and VGP stages, when Beta3 is expressed.


Social

Follow Science a GoGo


Home         All The News      Science Forum         Books, Books, Books         Curiosity Shop         About

The terms and conditions governing your use of this website.
Copyright © 1997 - 2012 Science a Go Go and its licensors. All rights reserved.